Day two of bionano's next-generation cytogenomics symposium: saphyr outperforms standard cytogenetics in heme malignancies, is less expensive, provides actionable information faster, in single assay

San diego, jan. 13, 2021 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) announced that day two of its five-day next-generation cytogenomics symposium featured eight saphyr users presenting their results and experiences using the saphyr® system for optical genome mapping (ogm) to analyze the genomes of patients with heme malignancies. the presentations by scientists and clinicians from leading hospitals and medical research institutions in europe, the us and china discussed results on a variety of blood cancers, including myelodysplastic syndromes and a number of acute and chronic leukemias, and all 8 studies showed that saphyr-based analyses of hematological malignancies can identify actionable variants detected by several cytogenomic methods combined, find additional important variants missed by traditional methods with prognostic and therapeutic value, and can do so with a shorter turn-around time and at a lower cost.
BNGO Ratings Summary
BNGO Quant Ranking